Obesity in Seniors, Finally Treated
Nearly 40% of adults over 60 in the US were obese in 2023. For people aged 65 and older, excess weight is a major driver of complications, reduced quality of life, and disability. Yet for years, clinicians lacked robust data on whether the new generation of GLP-1 weight-loss drugs actually work in this age group — and more importantly, whether they are safe. Older adults were underrepresented in the STEP trials that established semaglutide (Wegovy, Ozempic) as a revolutionary obesity therapy.
That evidence gap is now closed. A new pooled analysis of the STEP program — presented at the European Congress on Obesity (ECO2026) and led by Prof Luca Busetto from the University of Padova — finds that semaglutide delivers substantial weight loss and cardiometabolic improvements in adults over 65, with a safety profile consistent with the broader trial population. In short: seniors respond just as well as younger adults, and the drug appears safe enough to prescribe.
Among 358 participants aged ≥65, those randomized to semaglutide 2.4 mg lost −15.4% of body weight over 68 weeks, compared to −5.1% on placebo. Two-thirds achieved at least 10% weight loss, and nearly half topped 15%. The same pattern of metabolic improvement held for waist circumference, blood pressure, cholesterol, and HbA1c. Adverse event rates were high but similar between groups; serious AEs were numerically higher with semaglutide (19.0% vs 12.7%), which clinicians must weigh against benefits.
Why does this matter? Because older adults account for the majority of excess weight cases in high-income countries. "Our results support the use of semaglutide in this patient group," says Prof Busetto. This article breaks down the numbers, places them in context, and explores what comes next for geriatric metabolic care.
How the Study Was Done
The analysis pooled individual participant data from six phase III STEP trials (STEP 1, 3, 4, 5, 8, and 9) sponsored by Novo Nordisk. These are randomized, double-blind, placebo-controlled trials that established semaglutide 2.4 mg weekly as a breakthrough for obesity. To isolate the drug's effect on weight without diabetes-induced variability, the pooled population excluded anyone with type 2 diabetes.
From the total N=4,523 across all six trials, the researchers identified 358 participants aged 65 years or older who met the obesity/overweight criteria: body mass index ≥30 kg/m², or ≥27 kg/m² with at least one obesity-related complication. All were randomized to either semaglutide 2.4 mg or placebo, and all received lifestyle intervention; the STEP 3 arm also included intensive behavioral therapy. Follow-up lasted 68 weeks, with outcomes assessed from baseline to week 68.
The cohort was typical of older adults with obesity: mean age 69 years, mean weight 99.0 kg, mean BMI 36.6 kg/m², mean waist circumference 115 cm, and 72% were female. Cru cially, 90% were in the 65–74 age bracket; only 10% were 75 or older. This age distribution mirrors real-world demographics but underscores the limited data on the “oldest old.”
Endpoints included percentage change in body weight, categorical weight-loss thresholds (≥10%, ≥15%, ≥20%), waist circumference, waist-to-height ratio (WHtR) <0.53, BMI category shifts, and cardiometabolic risk factors (blood pressure, lipids, HbA1c, hs-CRP). Adverse events were recorded systematically. This comprehensive panel allowed the researchers to assess both efficacy and safety in a vulnerable population often left out of drug development.
Weight Loss and Body Composition Results
The efficacy signal was clear and substantial. Over 68 weeks, the semaglutide 2.4 mg group achieved an average weight reduction of −15.4% from baseline, while the placebo group lost only −5.1%. The between-group difference of 10.3 percentage points is both statistically and clinically significant.
Even more impressive are the categorical thresholds. Over two-thirds (66.5%) of those on semaglutide achieved at least a 10% weight loss, compared to just 15.5% on placebo. For the tougher 15% milestone, the rates were 46.8% vs 6.4%. And 28.6% of semaglutide users lost 20% or more of their initial body weight — a result seen in only 2.7% of the placebo arm.
Waist circumference — a key marker of cardiometabolic risk — dropped by an average of 14.3 cm in the semaglutide group vs 6.0 cm with placebo. Similarly, the waist-to-height ratio (WHtR) improved: 11.3% of semaglutide participants reached WHtR <0.53 compared to 4.5% of those on placebo.
| Metric | Semaglutide | Placebo |
|---|---|---|
| Waist circumference change | −14.3 cm | −6.0 cm |
| WHtR <0.53 achieved | 11.3% | 4.5% |
| BMI <27 kg/m² (healthy weight) | 27.0% | 5.5% |
| Both BMI <27 and WHtR <0.53 | 10.5% | 2.7% |
The shift in BMI categories was dramatic. Over a quarter of the semaglutide group (27.0%) moved into the “healthy weight” range (BMI <27 kg/m²), versus just 5.5% with placebo. Consequently, the proportions of participants in all obesity classes (I, II, III) declined within the semaglutide arm. The dual target — healthy BMI plus healthy WHtR — was achieved by 10.5% of semaglutide users.
Cardiometabolic and Systemic Improvements
Weight loss alone does not capture the full benefit. The STEP analysis shows that semaglutide improves multiple cardiometabolic risk factors in older adults — a population already burdened by hypertension, dyslipidemia, and prediabetes. Compared to placebo, semaglutide-treated seniors experienced greater reductions in blood pressure, improvements in lipid profiles (cholesterol and blood fats), and lower glycated hemoglobin (HbA1c), indicating better blood sugar control.
These findings echo a broader trend in GLP-1 agonist research: the class consistently reduces major cardiovascular events in patients with type 2 diabetes and existing heart disease. Although this specific older adult analysis excluded individuals with diabetes, the HbA1c improvement suggests that even non-diabetic seniors could see meaningful metabolic benefits. The CDC estimates that nearly 40% of adults over 60 were obese in 2023 — a condition that fuels metabolic syndrome, heart disease, and even neurodegenerative disorders like Alzheimer's. For perspective, a separate recent study linked higher egg consumption to a 27% lower Alzheimer's risk; but managing obesity remains the most direct lever for metabolic health in aging populations.
Beyond numbers, the clinical significance lies in the potential to compress morbidity. Older adults with obesity often face a cascade of complications: mobility-limiting osteoarthritis, sleep apnea, increased cancer risk, and frailty. By shedding weight and improving cardiometabolic markers, patients may regain functional capacity, reduce medication burden, and delay disability. The fact that semaglutide's efficacy appears age-independent is crucial: seniors respond as robustly as younger adults, which contradicts earlier concerns that reduced muscle mass or slower metabolism would blunt the drug's effect.
Long-term data up to two years in broader STEP populations suggest these benefits are sustained, though analysis specifically in the ≥65 cohort beyond 68 weeks is still pending. Ongoing trials will clarify whether semaglutide can alter the trajectory of age-related functional decline, including impacts on sarcopenia and physical performance. For now, the available evidence supports a holistic health gain that goes beyond the scale.
Safety and Tolerability in Older Adults
Any weight-loss drug for seniors must clear a high bar for safety. Older adults are more frail, take more medications, and face greater risks from adverse events. The STEP pooled analysis provides a balanced view: overall adverse event (AE) rates were high but nearly identical between groups (89.1% semaglutide, 84.5% placebo) — expected in a 68-week trial with close monitoring. More telling are the serious adverse events (SAEs): 19.0% with semaglutide vs 12.7% with placebo, a numeric increase that warrants attention but must be interpreted in context.
The specific side effect profile aligns with what clinicians know about GLP-1 receptor agonists. Gastrointestinal symptoms predominated: constipation and dizziness occurred more frequently with semaglutide. These are typically mild to moderate and self-limited, but in older adults they can lead to dehydration or falls if not proactively managed. Two serious concerns often raised with GLP-1 drugs — fractures and hypoglycemia — were reassuring: rates were <1% in both groups and comparable to placebo. This suggests that bone health and low blood sugar are not major hazards in this non-diabetic older cohort.
The higher SAE rate in the semaglutide arm likely reflects a combination of factors: the drug itself causing some events (e.g., gastrointestinal), but also increased detection due to more frequent study contacts, and perhaps a sicker baseline population that nonetheless lost weight. The trial’s exclusion of people with diabetes may limit generalizability to older adults with comorbid T2D, where hypoglycemia risks could differ. Nonetheless, the overall safety signal remains consistent with the broader STEP program and with meta-analyses of other GLP-1 agonists.
Practical implications: clinicians should monitor older patients on semaglutide for GI intolerance, dizziness, and potential interactions with other medications. Gradual dose titration, hydration, and dietary adjustments can mitigate side effects. The data do not show a “dealbreaker” safety issue; rather, they reinforce the need for shared decision-making that weighs the impressive weight-loss and metabolic benefits against the known side effect burden in this vulnerable group.
What Comes Next for Semaglutide in Aging Populations
The STEP pooled analysis closes a critical evidence gap, but it also opens new questions. With obesity now prevalent in older adults, and with GLP-1 drugs becoming first-line pharmacotherapy, the research agenda must expand beyond efficacy to real-world effectiveness, cost-effectiveness, and impact on geriatric outcomes.
Key unanswered questions include: Does semaglutide preserve or harm muscle mass and functional status in seniors at risk for sarcopenia? How do the cardiometabolic benefits compare numerically between younger and older adults? What are the psychosocial effects of rapid weight loss and facial fat changes — the so-called “Ozempic face” — in an age group particularly sensitive to body image and social isolation? And is the drug cost-effective for healthcare systems when weighed against reduced disability and improved quality of life?
On the policy side, the rise of off-label semaglutide use for cosmetic weight loss raises ethical dilemmas about access and appropriate indications. The present study focuses on medically indicated obesity, but societal trends may push prescribing patterns in new directions. Clinicians will need tools to triage patients and monitor for side effects that may be more pronounced in older age.
For now, the evidence supports offering semaglutide to adults over 65 with obesity, after individualized risk-benefit discussion. The drug’s ability to shift BMI categories and improve risk factors could translate into meaningful reductions in diabetes incidence, cardiovascular events, and need for joint replacements — outcomes that directly affect seniors’ independence. As one researcher noted, the magnitude of weight loss mirrors that seen in younger adults, dispelling myths that older bodies don’t respond.
The full impact of GLP-1 therapy on healthy aging remains to be seen, but this analysis provides a solid foundation. Future studies should focus on the oldest old (≥75), on patients with diabetes, and on long-term (>2 year) outcomes including frailty indices and mortality. Continuous safety surveillance will be essential as real-world use expands.
If you’re interested in complementary science coverage, see our recent pieces on nutrition and Alzheimer’s risk, the KPZ universality physics breakthrough, and the fundamental constants fine-tuning discovery, as well as the limb regeneration genetic code.
This article was generated by AI based on research from multiple sources. While efforts are made to ensure accuracy, readers should verify information independently.
Post a Comment